エンジェルの会は、今年10月13日正式にASA（Angelman Syndrome Alliance)に加盟しました。ASAはEU各国の親の会が中心となって、アンジェルマン症候群の治療研究に助成金を出すことで、少しでも研究開発を前に進めてもらおうという目的で結成されています。
350.000 EURO FOR RESEARCH ON ANGELMAN SYNDROME
Call for Applications for Research Grants on Angelman Syndrome
Deadline 4th January 2019
The Angelman Syndrome Alliance (ASA) supports research on Angelman syndrome with up to 300.000,- Euro to be awarded at the next International Angelman Syndrome Scientific Conference. The Angelman Syndrome Alliance is an initiative of the following parent organizations ASB (Belgium), ASFA (France), Angelman e.V. (Germany), ORSA (Italy), AIA (Ireland), AV (Netherlands), Angel (Portugal), Angelman UK (United Kingdom), AVO (Austria), Israeli AS Foundation(Israel), JASSG (Japan), Spain (ASA) and the Nina Foundation (Netherlands) who have created an international organization on AS science. Their mutual aim is to join forces and funds to increase the financial support of dedicated research projects and thereby intensify research on Angelman Syndrome.
Angelman Syndrome is a genetic disorder that results from a loss of UBE3A gene activity which encodes the ubiquitin E3 ligase E6-AP. Angelman Syndrome is characterised by severe intellectual disability, lack of speech, motor coordination deficits, sleep disturbance, and usually a happy demeanour.
Researchers of any country are invited to apply for research grants covering preclinical (basic) research as well as translational research such as mechanism based controlled trials. Applications for behavioural therapies are not eligible at this point.
Grants awarded for up to € 175,000 per grant. The duration of the grant is flexible, but the maximum duration is 4 years. There will be an evaluation of the project after completion of 50% of the anticipated grant duration; this should be in form of a detailed written scientific report for the SAB and a report with pictures in simple language to share with the funding parents organisations in more general terms.
The application procedure is two-step: first, a short application has to be submitted on the ASA website (Deadline 4th January 2019); a detailed application will then be invited in the end of 14th January 2019 from those proposals passing step 1 (Deadline 11th March). The applicants will be informed about the outcome of the call 22nd July 2019. The awardees will be invited to give the ASA-AWARD LECTURE at the next bi-annual ASA scientific conference in fall 2020.
Registering for the grant can be done via the ASA website www.angelmanalliance.org
The short application should include the following:
- Cover letter including the title of the proposal and the name of the principal investigator
- Two-page summary of the proposed research including paragraphs on the hypothesis, background, research plan, principal methodology, and the significance of the proposed research. An overview of the budget must also be included (indirect costs cannot be applied for).
- Curriculum vitae of the applicant
All applications should be written in English language using Times New Roman, 10 point, 1.5 spaced.
Proposals involving laboratory animal testing must be approved by the respective institutional review boards before funding can be released.
All proposals, including cover letters, should be uploaded at the ASA website: angelmanalliance.org
à Questions about the process of the grant should be directed to the ASA Board at: Manuel Duarte – email@example.com
à Questions about research on Angelman Syndrome should be directed to the Scientific Advisory Board at: Harald Sitte – firstname.lastname@example.org